Money Talks in Hospitals’ Adoption of Oncology Biosimilars
Hospitals’ use of biosimilars for three major oncology drugs increased from 18-37% in 2020 to 84-93% in 2024.Hospitals’…
Comparative Real-World Effectiveness of Rituximab vs Cladribine in Relapsing-Remitting Multiple Sclerosis
In the changing landscape of relapsing-remitting multiple sclerosis (RRMS), decisions around aggressive treatments rest on clinical trial data…